Keywords: FORMA Therapeutics, Janssen, Johnson & Johnson, Tumor metabolisn targets

Another mega deal for FORMA Therapeutics

Article | 11 January 2012

Print This

Hot on the heels of its up to $815 million oncology-related deal with Boehringer Ingelheim (The Pharma Letter January 6), US drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in